A high-throughput screening assay using Krabbe disease patient cells

Analytical Biochemistry

Volumn 434, Issue 1, 2013, Pages 15-25

  Ribbens, Jameson ^a   Whiteley, Grace ^b   Furuya, Hirokazu ^c   Southall, Noel ^b   Hu, Xin ^b   Marugan, Juan ^b   Ferrer, Marc ^b   Maegawa, Gustavo H B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NHO Omuta Hospital   (Japan)

Author keywords

High throughput screening; Krabbe disease; Small molecules; Galactocerebrosidase

Indexed keywords

BONE; CELL CULTURE; DIAGNOSIS; FIBROBLASTS; MOLECULES; PATIENT TREATMENT;

BIOCHEMICAL CHARACTERISTICS; BONE MARROW TRANSPLANTATION; COMPOUND COLLECTIONS; HIGH THROUGHPUT SCREENING; NEURODEGENERATIVE DISORDERS; NEUROLOGICAL MANIFESTATIONS; SMALL MOLECULES; THERAPEUTIC POTENTIALS;

NEURODEGENERATIVE DISEASES;

BETA GALACTOSIDASE; GALACTOSYLCERAMIDASE; GLUCOSYLCERAMIDASE; VIRUS LARGE T ANTIGEN;

ARTICLE; BLOOD BRAIN BARRIER; CELL COUNT; CELL LYSATE; CELL TRANSFORMATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DEGENERATIVE DISEASE; ENZYMATIC ASSAY; ENZYME ACTIVITY; FIBROBLAST; FIBROBLAST CULTURE; GLOBOID CELL LEUKODYSTROPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKOCYTE; MISSENSE MUTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIMIAN VIRUS 40; SKIN FIBROBLAST; VIRUS TRANSFORMATION;

EID: 84872859868     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.10.034     Document Type: Article

References (29)

1. M.A. Rafi, P. Luzi, J. Zlotogora, and D.A. Wenger Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel Hum. Genet. 97 1996 304 308
2. D.A. Wenger, M.A. Rafi, and P. Luzi Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications Hum. Mutat. 10 1997 268 279
3. H. Furuya, Y. Kukita, S. Nagano, Y. Sakai, Y. Yamashita, H. Fukuyama, Y. Inatomi, Y. Saito, R. Koike, S. Tsuji, Y. Fukumaki, K. Hayashi, and T. Kobayashi Adult onset globoid cell leukodystrophy (Krabbe disease): analysis of galactosylceramidase cDNA from four Japanese patients Hum. Genet. 100 1997 450 456
4. A. Fiumara, R. Barone, A. Arena, M. Filocamo, W. Lissens, L. Pavone, and G. Sorge Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G>A (p.Gly41Ser) mutation Clin. Genet. 80 2011 452 458
5. J.E. Deane, S.C. Graham, N.N. Kim, P.E. Stein, R. McNair, M.B. Cachon-Gonzalez, T.M. Cox, and R.J. Read Insights into Krabbe disease from structures of galactocerebrosidase Proc. Natl. Acad. Sci. USA 108 2011 15169 15173
6. K. Suzuki Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status Neurochem. Res. 23 1998 251 259
7. L. Svennerholm, M.T. Vanier, and J.E. Mansson Krabbe disease: a galactosylsphingosine (psychosine) lipidosis J. Lipid Res. 21 1980 53 64
8. T.A. Burrow, R.J. Hopkin, N.D. Leslie, B.T. Tinkle, and G.A. Grabowski Enzyme reconstitution/replacement therapy for lysosomal storage diseases Curr. Opin. Pediatr. 19 2007 628 635
9. M.L. Escolar, M.D. Poe, J.M. Provenzale, K.C. Richards, J. Allison, S. Wood, D.A. Wenger, D. Pietryga, D. Wall, M. Champagne, R. Morse, W. Krivit, and J. Kurtzberg Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease N. Engl. J. Med. 352 2005 2069 2081
10. P.K. Duffner, V.S. Caviness Jr., R.W. Erbe, M.C. Patterson, K.R. Schultz, D.A. Wenger, and C. Whitley The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York Genet. Med. 11 2009 450 454
11. E. Conzelmann, and K. Sandhoff Partial enzyme deficiencies: residual activities and the development of neurological disorders Dev. Neurosci. 6 1983 58 71
12. G.H. Maegawa, M. Tropak, J. Buttner, T. Stockley, F. Kok, J.T. Clarke, and D.J. Mahuran Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis J. Biol. Chem. 282 2007 9150 9161
13. G.H. Maegawa, M.B. Tropak, J.D. Buttner, B.A. Rigat, M. Fuller, D. Pandit, L. Tang, G.J. Kornhaber, Y. Hamuro, J.T. Clarke, and D.J. Mahuran Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease J. Biol. Chem. 284 2009 23502 23516
14. J.J. Marugan, W. Zheng, O. Motabar, N. Southall, E. Goldin, W. Westbroek, B.K. Stubblefield, E. Sidransky, R.A. Aungst, W.A. Lea, A. Simeonov, W. Leister, and C.P. Austin Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity J. Med. Chem. 54 2011 1033 1058
15. O. Motabar, E. Goldin, W. Leister, K. Liu, N. Southall, W. Huang, J.J. Marugan, E. Sidransky, and W. Zheng A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide Anal. Bioanal. Chem. 402 2012 731 739
16. W. Zheng, J. Padia, D.J. Urban, A. Jadhav, O. Goker-Alpan, A. Simeonov, E. Goldin, D. Auld, M.E. LaMarca, J. Inglese, C.P. Austin, and E. Sidransky Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease Proc. Natl. Acad. Sci. USA 104 2007 13192 13197
17. H. Geng, G. Whiteley, J. Ribbens, W. Zheng, N. Southall, X. Hu, J.J. Marugan, M. Ferrer, and G.H. Maegawa Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease PLoS One 6 2011 e29504
18. G. Wiederschain, S. Raghavan, and E. Kolodny Characterization of 6-hexadecanoylamino-4-methylumbelliferyl-β-d-galactopyranoside as fluorogenic substrate of galactocerebrosidase for the diagnosis of Krabbe disease Clin. Chim. Acta 205 1992 87 96
19. W.C. Lee, D. Kang, E. Causevic, A.R. Herdt, E.A. Eckman, and C.B. Eckman Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones J. Neurosci. 30 2010 5489 5497
20. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
21. M. Chatelut, K. Harzer, H. Christomanou, J. Feunteun, M.T. Pieraggi, B.C. Paton, Y. Kishimoto, J.S. O'Brien, J.P. Basile, J.C. Thiers, R. Salvayre, and T. Levade Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies Clin. Chim. Acta 262 1997 61 76
22. J. Inglese, D.S. Auld, A. Jadhav, R.L. Johnson, A. Simeonov, A. Yasgar, W. Zheng, and C.P. Austin Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries Proc. Natl. Acad. Sci. USA 103 2006 11473 11478
23. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
24. J.E. Mansson, and L. Svennerholm The use of galactosylceramides with uniform fatty acids as substrates in the diagnosis and carrier detection of Krabbe disease Clin. Chim. Acta 126 1982 127 133
25. K. Suzuki, and Y. Suzuki Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside-β-galactosidase Proc. Natl. Acad. Sci. USA 66 1970 302 309
26. C. Hohenschutz, W. Friedl, K.H. Schlor, A. Waheed, E. Conzelmann, K. Sandhoff, and P. Propping Probable metachromatic leukodystrophy/pseudodeficiency compound heterozygote at the arylsulfatase A locus with neurological and psychiatric symptomatology Am. J. Med. Genet. 31 1988 169 175
27. J.T. Clarke, D.J. Mahuran, S. Sathe, E.H. Kolodny, B.A. Rigat, J.A. Raiman, and M.B. Tropak An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants) Mol. Genet. Metab. 102 2011 6 12
28. S. Ishii Pharmacological chaperone therapy for Fabry disease Proc. Jpn. Acad. B 88 2012 18 30
29. T.W. Mu, D.S. Ong, Y.J. Wang, W.E. Balch, J.R. Yates III, L. Segatori, and J.W. Kelly Chemical and biological approaches synergize to ameliorate protein-folding diseases Cell 134 2008 769 781